Gilead Sciences Annual Report 2010 Our Science Connects Us
Desiree is connected to the members of her church, to the patients she helps as a respiratory therapist and to the other long-distance runners she meets while training. She s connected to Isaac, the two-year-old grandson she adores. Through the HIV treatment she takes every day, she is also connected to Gilead. Identifying and develop ing new compounds and combinations that have the potential to transform the way diseases are treated. In the Lab Around the World Supplying lifeenhancing medicines across the globe through efficient manufacturing and distribution operations. Supporting Desiree and other people living with serious diseases is the goal of everything we do at Gilead and our science is what makes it possible. It is this focus on science that drives us to discover new compounds and develop new partnerships that help us grow our pipeline. Our science doesn t stop after a drug is approved; it continues on, connecting healthcare providers with the data they need to keep their patients informed. And it shapes the way we make our treatments accessible to patients, connecting medicine to people in need around the world. Our science connects the way we think, how we work and the way we and the many patients we serve live every day. Working with providers to deliver the kind of quality care that optimizes patient outcomes. At the Clinic With our Partners Collaborating with industry, government and community to ensure our products reach the people who need them, wherever they live. Providing people who live with serious diseases with the support they need to make informed decisions about their therapeutic options. With Patients < On the cover: Desiree, living with HIV, Truvada patient and Isaac, grandson of Desiree 1
Our Science Connects Us In the Lab Over the past 15 years, combination therapy has revolutionized HIV treatmen t first transforming a deadly disease into a chronic, manageable condition, and later enabling many patients to have the convenience of taking just one pill, once a day. Could a similar approach lead to better treatments for chronic hepatitis C? Maisoun, Guofeng and other Gilead researchers think it could. Chronic hepatitis C virus (HCV) infection is a leading cause of cancer and liver transplantation, affecting approximately 200 million people worldwide. Existing treatments do not work for the majority of patients and are often accompanied by serious, debilitating side effects. Investigational oral antiviral treatments that specifically attack HCV at different stages of its lifecycle are being developed to be easier to use and more effective, with fewer side effects. Gilead is currently testing seven unique molecules with six different mechanisms of action, which could be used in combinations to suppress HCV and potentially cure HCV infection. My colleagues and I are dedicated to moving potential HCV candidates through the lab as quickly as possible, so that patients have better treatment options in the future. Guofeng Cheng, PhD Gilead Foster City < Maisoun Sulfab, Senior Research Associate, Gilead Sciences (left) and Guofeng Cheng, PhD, Research Scientist, Gilead Sciences (right) 3
Our Science Connects Us At the Clinic Cystic fibrosis (CF) is a challenging disease to treat but with Gilead s help, Dr. Marcia Katz is making sure her patients get optimal treatment. Marla is now using Cayston, Gilead s new inhaled antibiotic, which helps her breathe a little easier. Gilead developed Cayston in close partnership with the Cystic Fibrosis Foundation s clinical trials network to meet the real needs of people living with CF. Specifically, patients can take Cayston in less than five minutes, three times a day an important advance in reducing the burden of daily treatment. Exciting new data recently presented at a medical conference showed that Cayston provides greater improvement in lung function than the only other existing inhaled antibiotic treatment. Gilead continues to conduct clinical research to help physicians provide the best care to CF patients. Patients like Marla are such an inspiration to me. I m always focused on finding new therapeutic options so she can get the most out of life. We re both delighted with the improvements she has seen with Cayston. Dr. Marcia Katz Baylor College of Medicine Houston, Texas < Marla, living with cystic fibrosis, Cayston patient (left) and Marcia F. Katz, MD, Brown Foundation Professor of Adult Cystic Fibrosis; Director, Adult Cystic Fibrosis Center; Associate Professor of Medicine, Baylor College of Medicine (right) 5
Our Science Connects Us With our Partners Hepatitis B virus (HBV) is a major health problem worldwide particularly in Asia, where the virus is endemic and some 10 percent of adults are chronically infected. About a quarter of infected adults will die from HBVrelated liver cancer or cirrhosis, resulting in some 300,000 deaths each year in China alone. Gilead s antiviral medication Viread received U.S. and European approval for the treatment of chronic HBV in 2008. Today, Enrico is working with our Hong Kong-based distribution partner IDS to bring Viread to HBV patients in Asia. We have already received regulatory approval in Taiwan and Hong Kong, and approval is pending in China, where we will collaborate with GlaxoSmithKline to commercialize the product. Building partnerships like these helps Gilead bring our science to patients in need, wherever they live. Our focus is to collaborate closely with Gilead on improving healthcare for hepatitis B patients in parts of Asia. Hepatitis B is a serious concern due to its high prevalence, and it is vital that Gilead is here to help us deliver new therapies for these patients. Samson Tsoi IDS Hong Kong < Samson Tsoi, General Manager Healthcare, Hong Kong and South China, IDS (Hong Kong) Limited (left) and Enrico Magnanelli, Director, Sales and Marketing, International Distribution, Gilead Sciences (right) 7
Providing treatment for millions of people globally who face life-threatening Our Science Connects Us Around the World diseases is a rewarding mission and a tremendous responsibility. Julie, Brendan, Lorraine and David are part of a team who work diligently in Gilead s Ireland operations to supply our medications to patients worldwide. Products packaged at the Cork manufacturing facility are transported to Dublin and then distributed directly to customers. The team in Dublin conducts rigorous quality assurance checks to ensure that every order meets local and international regulatory standards. The Ireland team also plays a critical role in supporting Gilead s Access Program in the developing world, by shipping HIV medicines from docks in Dublin to national procurement offices, hospitals and local clinics, and ultimately into the hands of patients throughout 130 resource-limited countries. < Julie O Neill, Vice President, Operations and General Manager, Gilead Sciences (left) and Brendan Power, Associate Manager, Shipping and Receiving, Gilead Sciences (right). Background: Lorraine Fitzpatrick, Customer Service Specialist, Gilead Sciences (left) and David Fitzgerald, Supervisor, Shipping and Receiving, Gilead Sciences (right). The logistical challenges in delivering medications to so many people in so many different countries can be complex. It is rewarding to know our daily efforts contribute to making the world a healthier place. Julie O Neill Gilead Ireland 9
Margaret is among approximately 10 million Americans living with the Our Science Connects Us chest pain, fear and discomfort of chronic angina. There is no cure for angina, With Patients ments like Gilead s Ranexa can minimize attacks and help patients return which is usually a symptom of underlying heart disease. However, treatto their activities. Gilead s sales force and medical experts reach out every day to provide cardiologists and internal medicine specialists with the information they need to keep angina patients healthy and active. Unlike many other angina treatments, Ranexa can be taken with a wide range of other heart medications, so Margaret and her doctor have been able to develop a comprehensive plan to help manage these painful attacks. < Harold, husband of Margaret (left) and Margaret, living with angina, Ranexa patient (right) After starting treatment with Ranexa, I traveled with my husband through the Rockies, at altitudes over 7,000 feet. To my great surprise, I experienced no chest pain and little fatigue. Margaret Living with angina Rusk, Texas 11
To Our Stockholders, Employees and Friends, At Gilead, success is defined by our ability to help people with life-threatening diseases around the world. Achieving this success now and in the future rests squarely on our science and on the ability to connect our knowledge to patients through our work in the laboratory, in the clinic and with partners and collaborators. I m very pleased to report that in 2010 we continued to deliver on this mission in many significant ways, while building upon a foundation that returns value to stockholders over the long term. Left to Right: Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer; Kristen M. Metza, Senior Vice President, Human Resources; Kevin Young, Executive Vice President, Commercial Operations; John C. Martin, PhD, Chairman and Chief Executive Officer; John F. Milligan, PhD, President and Chief Operating Officer; Robin L. Washington, Senior Vice President and Chief Financial Officer; Gregg H. Alton, Executive Vice President, Corporate and Medical Affairs. 2010 was a year of strong financial performance for Gilead, despite the challenging global economic environment. Annual revenues grew quarterover-quarter and year-over-year, reaching a record $7.9 billion for 2010, a 13 percent increase over 2009. This growth was due to increasing product sales in each of our core therapeutic areas in our key markets. Our strong financial performance is a testament to Gilead s innovative approach to our business an approach that is infused in every part of our organization from research laboratories to manufacturing and distribution facilities to sales and marketing teams. Our scientific approach drives how we think, how we work and, ultimately, how we make decisions to best serve the healthcare community and people living with unmet medical needs. Our science continues on long after a drug is approved, connecting doctors with the data they need to keep their patients informed, and connecting the right medicines to people in need around the world. Innovation in the Lab We pursue scientific discoveries through our internal programs and through collaboration with other research institutions and academia. Our rigorous scientific orientation combined with the emphasis we place on being good partners helps us attract collaborators interested in advancing the most promising compounds. For example, in 2005, we built on an existing marketing partnership and obtained exclusive rights from Japan Tobacco to develop and commercialize a novel HIV integrase inhibitor. That compound, elvitegravir, is currently undergoing Phase III clinical testing as both a stand-alone medication and a component of an investigational single-tablet antiretroviral regimen. Due to this collaborative approach, today we have more promising compounds in our research and development pipeline than ever before in our history. John C. Martin, PhD Chairman and Chief Executive Officer 13
$3500 $3000 $2500 $2000 $1500 $1000 $500 $0 Net Income ($ in millions) 08 09 10 Non-GAAP net income for 2008 excluded the after-tax impact of acquisition-related expenses of $7.8 million and the aftertax impact of stock-based compensation expenses of $112.8 million. Non-GAAP net income for 2009 excluded the after-tax impact of acquisition-related expenses of $49.3 million, the after-tax impact of restructuring expenses of $38.7 million and the after-tax impact of stock-based compensation expenses of $139.3 million. Non-GAAP net income for 2010 excluded the after-tax impact of acquisition-related expenses of $136.1 million, the after-tax impact of restructuring expenses of $29.3 million and the aftertax impact of stock-based compensation expenses of $147.7 million. GAAP Net Income Non-GAAP Net Income Even with the tremendous progress made in the treatment of HIV, we believe there will be an important role for new products with differentiated profiles, and we continue to have an active research program in this area. In addition to making significant progress on two new single-tablet regimens, we plan to advance clinical studies of a new nucleotide HIV reverse transcriptase inhibitor in 2011. Our research efforts also include the exploration of strategies for potentially curing the disease by eradicating the virus from the body of an infected individual. In the area of chronic hepatitis C a life-threatening disease for which there are limited treatment options our pipeline now includes seven unique molecules representing six drug classes with different mechanisms of action. Like HIV, the ultimate goal is the development of a complete oral combination regimen. With one of the broadest pipelines in the industry, our HCV research and development teams have an ambitious plan for 2011, involving studies of various combinations of these molecules, seeking to accelerate the development of combination treatments. Last year was also notable for the advances we made in cardiovascular and respiratory research. We continue to move these important research areas forward, along with efforts to identify new compounds. We completed the acquisition of CGI Pharmaceuticals in 2010, and in early 2011 we completed the acquisition of Arresto Biosciences and initiated the acquisition of Calistoga Pharmaceuticals. These additions to our business bring us an important library of proprietary small molecule kinase inhibitors with potential applications in the area of inflammation and promising therapeutics focused on fibrotic diseases and cancer. Making a Difference in the Clinic The ultimate aim of our research and development program is to bring new medicines that address significant unmet needs to physicians and their patients. 2010 marked a year of important progress in this regard. Evidence continues to build that taking a single-tablet regimen one pill, once a day for the treatment of HIV infection helps patients comply with prescription regimens, potentially lowering the risk of resistance and subsequent treatment failures. Since its launch nearly five years ago, Atripla has remained the only single-tablet regimen on the market. We expect that to change this year with our anticipated launch of an additional once-daily single-tablet regimen, which combines our two-drug therapy Truvada with TMC278, an investigational non-nucleoside reverse transcriptase inhibitor from Tibotec Pharmaceuticals. Over the course of the year, we made significant progress toward bringing patients another single-tablet regimen the once-daily four-in-one Quad, which combines Truvada with our investigational agents elvitegravir and cobicistat (a pharmacoenhancer). Data presented in September 2010 showed that this product maintained a high rate of virologic suppression at 48 weeks and exhibited antiretroviral efficacy comparable to that of Atripla, with fewer central nervous system side effects. We expect to complete both pivotal Phase III trials of the Quad by the end of 2011. We also now have exciting evidence that the therapies Gilead has developed for the treatment of HIV may help at-risk HIV-negative individuals avoid becoming infected with the virus. In November 2010, the National Institutes of Health-funded multi-country iprex study showed that once-daily use of Truvada reduced the risk of HIV infection among men who have sex with men by 44 percent overall and by 73 percent among HIV-negative men who were most adherent. Earlier in the year, South African researchers announced at the XVIII International AIDS Conference that a vaginal gel containing tenofovir the active ingredient in Viread helped to reduce the risk of contracting HIV among women by 39 percent. These developments are widely regarded as major steps forward in the battle against, offering hope that new prevention options may be available in the foreseeable future. Our commercial team plays an especially important role in bringing medicines to patients in need. With their deep expertise in each of our therapeutic areas, 14 15
$8000 $7000 $6000 $5000 $4000 $3000 Product Sales ($ in millions) Other Ranexa Letairis AmBisome Antiviral members of Gilead s sales and marketing groups work to develop programs that provide education and information to physicians and patients about the profile of our products and the ways we are working to address unmet medical needs. The results of these efforts are clear across our focus areas. For example, within the area of liver disease, Viread is now the most-prescribed treatment for chronic hepatitis B in the United States and Europe. At the same time, we are working to provide treatments that meet the needs of a wider range of patients. In 2010, both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency expanded Viread s existing indication for chronic hepatitis B to include the treatment of patients with decompensated liver disease based on data generated from clinical studies evaluating the therapy in this difficult-to-treat patient population. long-term safety and efficacy data that will help healthcare providers deliver the best care for their patients. Reaching Patients through Partnerships Partnerships play a central role in our ability to connect patients to the medicines they need. One of Gilead s earliest partnerships a 1991 collaboration with the Institute of Organic Chemistry and Biochemistry in Prague, Czech Republic and the Rega Institute for Medical Research in Leuven, Belgium led to the development of our nucleotide compounds Vistide for cytomegalovirus (CMV) retinitis, Viread and Hepsera for chronic hepatitis B. This collaboration, which continues today, exemplifies how we approach partnerships, with a view to identifying the best science and working through the challenges to deliver on its potential. $9000 $8000 $7000 $6000 $5000 $4000 $3000 Total Revenues ($ in millions) $2000 $1000 $0 08 09 10 In November 2010 at the annual meeting of the American Association for the Study of Liver Diseases, we shared promising Phase II data showing that a combination of our investigational hepatitis C compounds GS 9190 and GS 9256, used in conjunction with current standard of care therapies, produced substantial suppression of the hepatitis C virus within 28 days of treatment. Research on the antiviral combination is now moving forward, and we anticipate that a three or four drug oral treatment strategy may Over the years, we ve applied this approach to collaborations with industry peers, and we are very proud of our partnership with F. Hoffmann-La Roche, which commercializes the leading influenza treatment Tamiflu, our first-ofa-kind collaboration with Bristol-Myers Squibb to develop Atripla and our recent agreement with Tibotec Pharmaceuticals to develop the next antiretroviral single-tablet regimen of Truvada and TMC278. $2000 $1000 $0 08 09 10 become the new standard of care for chronic hepatitis C. In late 2009, the U.S. Department of Health and Human Services, the World In February 2010, the FDA approved Cayston for the treatment of pseudomonal infections in people living with cystic fibrosis, a life-threatening respiratory illness. Cayston is also now available in Austria, Canada, Germany and the United Kingdom. In November 2010, we presented data at the North American Cystic Fibrosis Annual Conference showing that the product use resulted in better lung function than the existing standard of care, inhaled tobramycin. We are currently exploring the potential of Cayston to address a wider range of serious respiratory diseases, including bronchiectasis. Health Organization and other public health agencies updated their HIV treatment guidelines, recommending that antiretroviral therapy be initiated earlier to improve patient outcomes. The impact of the guidelines began to be realized over the course of 2010, evidenced by an increase in the average CD4 cell count of patients initiating therapy. Nonetheless, currently in the United States, it is estimated that only half of the 1.2 million people living with HIV are receiving antiretroviral therapy. An estimated 21 percent remain unaware of their status and when diagnosis does occur, it is very often late in the course of disease, leading to sub-optimal treatment outcomes. Routine Some of the most important clinical work we do takes place after a medicine HIV testing could help these patients access life-saving care sooner and help is approved. Ongoing clinical studies in each of our core therapeutic areas them avoid unknowingly passing on the virus to others. This is an area of of focus exemplify our commitment to generating and communicating focus for many of the community organizations with whom we partner on educational programs. 16 17
$4000 $3500 $3000 Operating Cash Flow ($ in millions) We embrace partnerships with the advocacy community across all our therapeutic areas. Through these relationships, forged by conversations our field-based teams and individuals across our organization have every day, we gain a better understanding of the perspectives of patients and the needs of underserved and at-risk communities. The input and guidance of advocates has helped to shape many of our educational initiatives, as well as our approach to access to medicines. We Are All Connected Our science connects us to people and communities everywhere. Behind Gilead s science are our 4,000 employees, who go to work every day with the goal of strengthening the connections that allow us to develop and deliver medicines to people in need. We rely on our Board of Directors a group of extraordinary individuals to provide oversight and guidance as we work to achieve our vision. $2500 $2000 $1500 $1000 Our Worldwide Impact With the January 2011 opening of our newest affiliate office in Warsaw, Poland, Gilead now has commercial operations based in more than 20 countries worldwide. We continue to evaluate opportunities to expand our commercial presence in parts of the world where we believe we can build operations that best position the company to deliver our products to patients. Like many of our industry peers, we continue to navigate the obstacles posed by the external global economic environment. In the face of those challenges, we made tremendous progress in 2010 and we look ahead to exciting milestones that will drive our business in 2011 and well beyond. To underscore our commitment to returning value to our stockholders, over the course of 2010, we repurchased and retired more than $4.0 billion in Gilead stock $500 To reach even more patients globally, we work with a network of distributors or approximately 12 percent of our outstanding shares. $0 08 09 10 and multiple Indian generic manufacturers to whom we have licensed our technology for the development of generic versions of our HIV medications. These partners have expertise in delivering medications to patients in resource-limited settings. Distributors leverage their local expertise to accelerate local regulatory processes and to provide medical education to ensure local providers and patients are informed about the benefits and Over the long term, we believe the most valuable way to sustain and build value is to continue focusing on our science the science that drives us to identify novel therapies in areas of unmet medical need, best characterize the profile of our existing products and communicate the value our medications have to society. appropriate use of our products. Gilead s licensing collaborations help to As we move ahead together in 2011, I thank you for your interest in Gilead address the global demand for high-quality, low-cost HIV treatment. As of Sciences and your shared commitment to our goal of providing medicines December 2010, 2.1 million people worldwide were receiving one of Gilead s to people who need them most. HIV medications of which 1.4 million reside in the developing world. Sincerely, Gilead also reaches out to communities everywhere through our corporate grants program and the Gilead Foundation. In 2010, we supported diverse charitable events, medical education programs and community outreach initiatives around the world. John C. Martin, PhD Chairman and Chief Executive Officer 18 FORWARD-LOOKING STATEMENT This Annual Report contains forward-looking statements regarding our clinical studies and product candidates, including the anticipated completion date of certain clinical trials and the potential of our product candidates. Such statements are predictions and involve risks and uncertainties such that actual results may differ materially. Please refer to Gilead s Annual Report on Form 10-K for the period ended December 31, 2010, attached to this report, for the risks and uncertainties affecting Gilead s business. Gilead disclaims, and does not undertake, any obligation to update or revise any forward-looking statements in this report. 19
Gilead s Focus Areas LIVER DISEASE CARDIOVASCULAR RESPIRATORY Gilead is the market leader in HIV therapy, providing more than two million patients worldwide with medicines that combine antiviral potency and durability with safety and tolerability. Today, we are in the advanced stages of developing two new single-tablet regimens complete once-daily antiretroviral therapy in just one pill that could offer patients important new options. We expect to bring the first of these regimens, a combination of Truvada and TMC278, to market in the second half of 2011. The second single-tablet regimen, combining Truvada with our investigational agents elvitegravir and cobicistat, is currently in Phase III trials, with data expected by the end of 2011. Elvitegravir and cobicistat are also in late-stage trials as stand-alone agents. In addition, we are in the early stages of developing an investigational nucleotide reverse transcriptase inhibitor, GS 7340, a novel prodrug of tenofovir, which more efficiently delivers drug to cells and tissues where HIV replicates, resulting in lower systemic exposure and the potential for greater potency. Chronic viral hepatitis (hepatitis B and C) affects some 500 million people worldwide and can often lead to liver cirrhosis and cancer. Viread is now the most-prescribed treatment for chronic hepatitis B virus (HBV) infection in the United States and in the major markets of Europe. In 2010, Gilead and GlaxoSmithKline finalized an agreement regarding commercialization of Viread for HBV in Asia, where the disease is particularly prevalent, and we look forward to making this treatment option more widely available in the region. As many as two-thirds of people with HBV do not know they are infected, therefore, we continue to work closely with healthcare providers, public health experts and community leaders to increase awareness and screening for HBV. In the case of hepatitis C virus (HCV), existing treatments can cause serious side effects and do not work for many patients. To address this unmet need, we are now moving forward with studies of seven oral compounds with six different mechanisms of action to fight HCV. Pulmonary arterial hypertension (PAH), which affects an estimated 200,000 people worldwide, is a serious, some times fatal disease that can significantly limit an individual s ability to pursue everyday activities. Gilead s Letairis can help by preventing narrowing of the blood vessels that deliver oxygen-rich blood to the lungs. Gilead continues to work to address the unmet needs of people living with PAH through new research programs. Gilead, in partnership with GlaxoSmithKline, initiated the AMBITION study, the first large randomized clinical trial in PAH to compare first-line combination therapy to monotherapy a key outstanding question in PAH treatment. In addition, Gilead is developing cicletanine, an antihypertensive currently in Phase II trials for the treatment of PAH. Additionally, in 2010, we continued to expand efforts to educate healthcare providers and patients about Ranexa and chronic angina. Lung infections are a frequent cause of sickness and death in people living with cystic fibrosis (CF), a genetic disorder affecting approximately 70,000 people worldwide. Approved in the United States in February 2010, Gilead s Cayston is an inhaled antibiotic that treats Pseudomonas aeruginosa infection, a serious complication of CF, and is now being evaluated for potential treatment of another pathogen, Burkholderia cepacia. Tamiflu continues to be an important treatment for patients worldwide affected by seasonal flu. In the United States alone, as many as 50 million cases of flu are reported annually, resulting in some 150,000 hospitalizations. Tamiflu, which diminishes the duration and severity of flu symptoms, was developed by Gilead and is marketed worldwide by F. Hoffmann-La Roche for both the treatment and prevention of the virus.
Marketed Products Product Pipeline PRODUCT INDICATION PARTNERS CANDIDATE PHASE I PHASE II PHASE III Atripla Bristol-Myers Squibb Company efavirenz 600 mg/emtricitabine 200 mg/ (U.S., Western Europe, Canada) tenofovir disoproxil fumarate 300 mg Merck & Co., Inc. (Rest of World) Truvada/TMC278 Single-Tablet Regimen Filed for Marketing Approval Truvada Japan Tobacco Inc. (Japan) emtricitabine/tenofovir disoproxil fumarate Emtriva Japan Tobacco Inc. (Japan) emtricitabine Elvitegravir integrase inhibitor Integrase Single-Tablet Regimen Quad elvitegravir/truvada/cobicistat Cobicistat pharmacoenhancer Viread Japan Tobacco Inc. (Japan) tenofovir disoproxil fumarate GS 7340 nucleotide reverse transcriptase inhibitor LIVER DISEASE LIVER DISEASE Viread Chronic Hepatitis B GlaxoSmithKline Inc. tenofovir disoproxil fumarate (China, Japan, Saudi Arabia) Hepsera Chronic Hepatitis B GlaxoSmithKline Inc. adefovir dipivoxil (Asia, Latin America) GS 9190 non-nucleoside polymerase inhibitor GS 9256 NS3 protease inhibitor Hepatitis C Hepatitis C CARDIOVASCULAR Lexiscan Coronary Vasodilation Astellas Pharma Inc. (U.S., Canada) regadenoson injection Rapidscan (Europe and select other markets) Letairis Pulmonary Arterial GlaxoSmithKline Inc. ambrisentan Hypertension (Outside U.S.) (WHO Group 1) Ranexa Chronic Angina Menarini Group (Europe) ranolazine GS 9451 NS3 protease inhibitor GS 5885 NS5A inhibitor GS 9620 TLR-7 agonist GS 6620 nucleotide polymerase inhibitor CARDIOVASCULAR/METABOLIC Hepatitis C Hepatitis C Hepatitis C/Hepatitis B Hepatitis C RESPIRATORY Cayston aztreonam for inhalation solution Cystic Fibrosis Tamiflu Influenza A and B F. Hoffmann-La Roche Ltd oseltamivir phosphate (Worldwide) Cicletanine antihypertensive Ranolazine late sodium current inhibitor RESPIRATORY Pulmonary Arterial Hypertension Coronary Artery Disease/Diabetes Macugen Neovascular (wet) Eyetech, Inc. (U.S.) pegaptanib sodium injection Age-related Macular Pfizer Inc. (Outside U.S.) Degeneration Aztreonam for Inhalation Solution Aztreonam for Inhalation Solution Cystic Fibrosis (Burkholderia cepacia) Bronchiectasis OTHER Vistide cidofovir injection CMV Retinitis/AIDS INFLAMMATION/ONCOLOGY AmBisome Severe Fungal Infections Astellas Pharma Inc. (U.S., Canada) amphotericin B liposome Dainippon Sumitomo for injection Pharma Co., Ltd. (Japan) GS 6624 monoclonal antibody GS 6624 monoclonal antibody Idiopathic Pulmonary Fibrosis Solid Tumors Note: Does not include all product candidates in Phase I and excludes research and preclinical programs.
Corporate Information Board of Directors John C. Martin, PhD Chairman and Chief Executive Officer, Gilead Sciences James M. Denny Lead Independent Director, Gilead Sciences Board of Directors Paul Berg, PhD Nobel Prize Winner, Chemistry Cahill Professor, Emeritus, Stanford University John F. Cogan, PhD Senior Fellow, Hoover Institution, Stanford University Etienne F. Davignon Minister of State, Chairman, Genfina Carla A. Hills Chair and Chief Executive Officer, Hills & Company International Consultants Kevin E. Lofton President and Chief Executive Officer, Catholic Health Initiatives John W. Madigan Retired Chairman and Chief Executive Officer, Tribune Company Gordon E. Moore, PhD Retired Chairman and Chief Executive Officer, Intel Corporation Nicholas G. Moore Retired Global Chairman, PricewaterhouseCoopers Richard J. Whitley, MD Distinguished Professor, Loeb Scholar Chair in Pediatrics, Professor of Pediatrics, Microbiology, Medicine and Neurosurgery, University of Alabama at Birmingham Gayle Edlund Wilson Chair, Ralph M. Parsons Foundation Per Wold-Olsen Retired President, Human Health Intercontinental Division, Merck & Co., Inc. Director Emeritus, Gilead Sciences Board of Directors George P. Shultz, PhD Distinguished Fellow, Hoover Institution, Stanford University Senior Leadership Team John C. Martin, PhD Chairman and Chief Executive Officer John F. Milligan, PhD President and Chief Operating Officer Norbert W. Bischofberger, PhD Executive Vice President, Research and Development and Chief Scientific Officer Gregg H. Alton Executive Vice President, Corporate and Medical Affairs Kevin Young Executive Vice President, Commercial Operations Kristen M. Metza Senior Vice President, Human Resources Robin L. Washington Senior Vice President and Chief Financial Officer Scientific Advisory Board Joel R. Huff, PhD (Chairperson) Retired Vice President, Medicinal Chemistry, Merck Research Laboratories Francis V. Chisari, MD Professor of Virology, The Scripps Research Institute Peter B. Dervan, PhD Bren Professor of Chemistry, California Institute of Technology Paul E. Klotman, MD President and Chief Executive Officer, John E. and Clara B. Whitmore Professor, Baylor College of Medicine John W. Mellors, MD Professor of Medicine, Chief, Division of Infectious Diseases, University of Pittsburgh School of Medicine Eugene R. Schiff, MD Leonard Miller Professor of Medicine, Director for Schiff Liver Institute, Director for Center for Liver Diseases, University of Miami School of Medicine Robert T. Schooley, MD Professor of Medicine and Head, Division of Infectious Diseases, Vice Chair of Department of Medicine, University of California, San Diego Eric J. Topol, MD Director, Scripps Translational Science Institute, Chief Academic Officer, Scripps Health Vice-Chairman, West Wireless Health Institute, Professor of Translational Genomics, The Scripps Research Institute Bernard M. Wagner, MD Emeritus Research Professor of Pathology, New York University Medical Center Health Policy Advisory Board Sir Richard Feachem, KBE, FREng, DSc(Med), PhD (Chairperson) Executive Director, UCSF Global Health Sciences, Director, Global Health Group, Professor of Global Health, University of California, San Francisco and University of California, Berkeley Seth F. Berkley, MD Founder, President and Chief Executive Officer, International AIDS Vaccine Initiative Ernest Darkoh, MD, MPH, MBA Founding Partner, BroadReach Healthcare Michael V. Drake, MD Chancellor, University of California, Irvine David Gollaher, PhD President and Chief Executive Officer, California Healthcare Institute Robert Shapiro, PhD Chairman, Sonecon, LLC Richard J. Whitley, MD Distinguished Professor, Loeb Scholar Chair in Pediatrics, Professor of Pediatrics, Microbiology, Medicine and Neurosurgery, University of Alabama at Birmingham Per Wold-Olsen Retired President, Human Health Intercontinental Division, Merck & Co., Inc. Corporate Secretary Gregg H. Alton Executive Vice President, Corporate and Medical Affairs Independent Registered Public Accountants Ernst & Young LLP Palo Alto, California Corporate Headquarters Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 USA (800) 445-3235 or (650) 574-3000 www.gilead.com Stockholder Inquiries Inquiries from our stockholders and potential investors regarding our company are always welcome and will receive a prompt response. Please direct your requests for information to: Investor Relations Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 USA (800) 445-3235 or (650) 574-3000 investor_relations@gilead.com Information regarding Gilead is also available at www.gilead.com. Stock Listing Gilead common stock is traded on The Nasdaq Global Select Stock Market, under the symbol GILD. Annual Meeting The annual meeting of stockholders will be held at 10:00 a.m. on Thursday, May 12, 2011 at the Westin San Francisco Airport Hotel. Transfer Agent and Registrar Communications concerning stock transfer requirements, lost certificates and changes of address should be directed to the Transfer Agent: BNY Mellon Shareowner Services 480 Washington Boulevard Jersey City, NJ 07310-1900 USA (800) 710-0940 www.bnymellon.com Equal Opportunity Employer Gilead Sciences is proud to be an equal opportunity employer and extends employment to men and women from culturally diverse backgrounds. Our environment respects individual differences and recognizes each employee as an integral member of our company. Our workforce reflects these values and celebrates the individuals who make up our growing team. Design: Howry Design Associates / SF Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific. AmBisome, Cayston, Emtriva, Gilead, the Gilead logo design, Hepsera, Letairis, Ranexa, Truvada, Viread, Vistide and Volibris are registered trademarks of Gilead Sciences, Inc. or its related companies. Atripla is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC. Lexiscan is a registered trademark of Astellas US LLC. Tamiflu is a registered trademark of Hoffmann-La Roche Inc. Macugen is a registered trademark of Eyetech, Inc. 24 Full U.S. prescribing information for Gilead products is available at www.gilead.com
Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 t 650 574 3000 f 650 578 9264 800 GILEAD-5 800 445 3235 www.gilead.com